DUBLIN, May 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences.
Jefferies Healthcare Conference
Date/Time: Wednesday, June 7, 2023 at 10:00 a.m. EDT (3:00 p.m. BST)
Goldman Sachs 44th Annual Global Healthcare Conference
Date/Time: Monday, June 12, 2023 at 9:20 a.m. PDT (12:20 p.m. EDT/5:20 p.m. BST)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Bernard
Investor Relations
+1 781 873 2402
| Last Trade: | US$24.68 |
| Daily Change: | 0.24 0.98 |
| Daily Volume: | 968,493 |
| Market Cap: | US$4.180B |
April 24, 2024 February 15, 2024 | |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
